文献速递泌尿生殖与妇科肿瘤放疗

局部晚期宫颈癌患者放化疗期间肿瘤缩小:预后意义及对影像引导自适应近距离放疗的影响

Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-06-18

研究纳入2004年2月至2015年11月在本机构连续接受同步放化疗(45 Gy/25次±淋巴结推量)后行MRI引导自适应脉冲剂量率近距离放疗的宫颈癌患者,评估治疗前及近距离放疗时GTV缩小的预后价值。247例可评估患者中,放化疗后完全缓解75例(28%);GTV诊断时55 cm3、近距离放疗时7.5 cm3、GTV缩小≥90%为最佳截断值,超过或低于这些截断值的患者总生存、无进展生存、局部控制及远处转移控制均显著降低(P < .001)。

要点

  • 247例局部晚期宫颈癌患者放化疗后完全缓解75例(28%)。
  • GTV最佳截断值:诊断时55 cm3、近距离放疗时7.5 cm3、缩小≥90%。
  • 体积高于或缩小低于上述截断值者OS、PFS、LC、DMC均显著降低(P < .001)。

核心结论

  • 这些结果可为放化疗后GTV体积缩小达到最优的患者开展近距离放疗剂量降阶梯研究提供依据,并可能强化对反应不佳患者进行剂量升阶梯的必要性。

研究设计与样本

  • 纳入2004年2月至2015年11月在本机构连续接受同步放化疗(45 Gy/25次±淋巴结推量)后行磁共振成像引导自适应脉冲剂量率近距离放疗的宫颈癌患者临床记录。
  • 在初始分期磁共振成像及近距离放疗时评估GTV及其放化疗后变化,所有测量及截断值采用3年无进展生存的时间依赖曲线下面积选择。
  • 共有247例患者可评估诊断至近距离放疗时的GTV变化。

主要发现

  • 放化疗后完全缓解见于75例患者(28%)。
  • 最佳截断值为诊断时GTV=55 cm3、近距离放疗时GTV=7.5 cm3、GTV缩小≥90%。
  • 所有体积高于或缩小低于上述截断值的患者总生存、无进展生存、局部控制及远处转移控制均显著降低(P < .001)。
  • 诊断时贫血的患者肿瘤体积反应率较低(P < .001)。
  • 多变量分析纳入国际妇产科联盟分期、N+分期、贫血及影像引导自适应近距离放疗剂量学参数后,放化疗后GTV最佳体积缩小与总生存、无进展生存、局部控制及远处转移控制改善独立相关(P < .001)。

关键数值与推荐

  • 诊断时GTV最佳截断值为55 cm3。
  • 近距离放疗时GTV最佳截断值为7.5 cm3。
  • GTV缩小最佳截断值为≥90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the prognostic value of gross tumor volume (GTV) shrinkage and its dosimetric implication in a large cohort of patients with cervical cancer receiving definitive chemoradiotherapy plus image guided adaptive brachytherapy. METHODS AND MATERIALS: Clinical records of consecutive patients treated in our institution between February 2004 and November 2015 by concurrent chemoradiotherapy (45 Gy in 25 fractions ± lymph node boosts) followed by a magnetic resonance imaging-guided adaptive pulse-dose rate brachytherapy were included. The prognostic value of GTV and its evolution after chemoradiotherapy were examined first on initial staging magnetic resonance imaging and then at time of brachytherapy. All measures and measurement cutoffs were selected using time-dependent area under the curve for 3-year progression-free survival (PFS). RESULTS: GTV evolution between diagnosis and the time of brachytherapy was assessed in 247 patients. After chemoradiotherapy, complete response was observed in 75 patients (28%). Optimal cutoffs were GTV = 55 cm3 at diagnosis, GTV = 7.5 cm3 at brachytherapy, and GTV reduction ≥90%. All patients with volume above or reduction below these cutoffs had significant reduced overall survival, PFS, local control, and distant metastasis control (P < .001). Patients with anemia at diagnosis had a lower tumor volume response rate (P < .001). In multivariate analysis, incorporating the International Federation of Gynecology and Obstetrics stage, N+ stage, anemia, and dosimetric parameters for image guided adaptive brachytherapy, GTV optimal volume reduction after chemoradiotherapy was independently associated with improved overall survival, PFS, local control, and distant metastasis control (P < .001). CONCLUSIONS: These results could provide a rationale for dose de-escalation studies in brachytherapy for patients displaying optimal GTV volumetric reduction after chemoradiotherapy and may reinforce the need for dose escalation in poorly responding patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Schernberg A, Bockel S, Annede P, et al. Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29920324. doi:10.1016/j.ijrobp.2018.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。